Literature DB >> 17090770

Prevention of malaria in long-term travelers.

Lin H Chen1, Mary E Wilson, Patricia Schlagenhauf.   

Abstract

CONTEXT: Long-term travelers, defined here as those traveling for periods of 6 months or longer, face particular challenges regarding malaria prevention. Current guidelines for malaria prevention primarily address prevention of Plasmodium falciparum infections in short-term travelers.
OBJECTIVES: To examine the risk of malaria in long-term travelers, recent developments in personal protective measures, and the safety and tolerability of malaria chemoprophylaxis during long-term use and to consider prevention strategies including continuous chemoprophylaxis, stand-by emergency self-treatment, seasonal prophylaxis, and strategies to prevent primary infection and relapses from P vivax malaria. EVIDENCE ACQUISITION: Comprehensive search of scientific publications including MEDLINE via both OVID and PubMED for relevant studies and articles with a cutoff date of July 2006, using the search terms long-term travel and malaria prevention, long-term malaria chemoprophylaxis, and insect repellent and malaria. Additional references were obtained from searching the bibliographies of the selected articles, from dissertations, and from the proceedings of relevant conferences on travel medicine. There were no language restrictions. EVIDENCE SYNTHESIS: Long-term travelers have a higher risk of malaria than short-term travelers. Long-term travelers underuse personal protective measures and adhere poorly to continuous chemoprophylaxis regimens. A number of strategies are used during long-term stays: discontinuation of chemoprophylaxis after the initial period, sequential regimens with different medications for chemoprophylaxis, stand-by emergency self-treatment, and seasonal chemoprophylaxis targeting high-incidence periods or locations. All strategies have advantages and drawbacks. Counterfeit drugs sold in countries endemic for malaria pose serious concern for long-term travelers who purchase their medications overseas. Vivax malaria causes significant illness in travelers, but relapses of vivax malaria are not prevented with the current first-line chemoprophylaxis regimens. Consensus guidelines are needed for prevention of malaria in long-term travelers.
CONCLUSIONS: Prevention of malaria in long-term travelers is a complex issue and requires expert advice from travel medicine specialists. Recommendations for prevention of malaria in long-term travelers must be individualized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090770     DOI: 10.1001/jama.296.18.2234

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  27 in total

1.  Malaria Disease and Chemoprophylaxis Usage among Israeli Travelers to Endemic Countries.

Authors:  Reut Harel; Bibiana Chazan; Eli Schwartz
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

2.  Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013.

Authors:  Keren Z Landman; Kathrine R Tan; Paul M Arguin
Journal:  Travel Med Infect Dis       Date:  2014-12-11       Impact factor: 6.211

3.  Mefloquine damage vestibular hair cells in organotypic cultures.

Authors:  Dongzhen Yu; Dalian Ding; Haiyan Jiang; Daniel Stolzberg; Richard Salvi
Journal:  Neurotox Res       Date:  2010-09-22       Impact factor: 3.911

4.  Risk for malaria in United States donors deferred for travel to malaria-endemic areas.

Authors:  Bryan Spencer; Whitney Steele; Brian Custer; Steven Kleinman; Ritchard Cable; Susan Wilkinson; David Wright
Journal:  Transfusion       Date:  2009-11       Impact factor: 3.157

Review 5.  Malaria chemoprophylaxis: strategies for risk groups.

Authors:  Patricia Schlagenhauf; Eskild Petersen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Business travel-associated illness: a GeoSentinel analysis.

Authors:  Lin H Chen; Karin Leder; Kira A Barbre; Patricia Schlagenhauf; Michael Libman; Jay Keystone; Marc Mendelson; Philippe Gautret; Eli Schwartz; Marc Shaw; Sue MacDonald; Anne McCarthy; Bradley A Connor; Douglas H Esposito; Davidson Hamer; Mary E Wilson
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

7.  Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis.

Authors:  Remington L Nevin
Journal:  Malar J       Date:  2009-08-05       Impact factor: 2.979

8.  Modeling the risk of malaria for travelers to areas with stable malaria transmission.

Authors:  Eduardo Massad; Ronald H Behrens; Marcelo N Burattini; Francisco A B Coutinho
Journal:  Malar J       Date:  2009-12-16       Impact factor: 2.979

9.  Illness in long-term travelers visiting GeoSentinel clinics.

Authors:  Lin H Chen; Mary E Wilson; Xiaohong Davis; Louis Loutan; Eli Schwartz; Jay Keystone; Devon Hale; Poh Lian Lim; Anne McCarthy; Effrossyni Gkrania-Klotsas; Patricia Schlagenhauf
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

10.  Summary of recommendations on malaria issues in special hosts.

Authors:  A Boggild; J Brophy; P Charlebois; M Crockett; J Geduld; W Ghesquiere; P McDonald; P Plourde; P Teitelbaum; M Tepper; S Schofield; A McCarthy
Journal:  Can Commun Dis Rep       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.